Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gritstone bio, Inc.

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease.With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			1.19M -	4.37M 267.73%	4.04M 7.51%	46.72M 1,057.22%	9.27M 80.16%	1.33M 85.64%
cost of revenue				82.90M -	88.64M 6.93%	14.40M 83.76%	15.69M 8.97%	7.59M 51.62%
gross profit			1.19M -	-78.53M 6,715.92%	-84.61M 7.74%	32.32M 138.20%	-6.42M 119.87%	-6.26M 2.52%
selling and marketing expenses								-7.59M -
general and administrative expenses	5.06M -	6.07M 19.91%	11.81M 94.43%	19.41M 64.40%	21.41M 10.31%	25.93M 21.12%	28.97M 11.71%	28.78M 0.65%
selling general and administrative expenses	5.06M -	6.07M 19.91%	11.81M 94.43%	19.41M 64.40%	21.41M 10.31%	25.93M 21.12%	28.97M 11.71%	21.19M 26.85%
research and development expenses	13.92M -	35.69M 156.47%	54.97M 54.00%	82.90M 50.82%	88.64M 6.93%	97.49M 9.98%	111.40M 14.27%	127.18M 14.16%
other expenses						-1.50M -	-10.68M 613.16%	-32K 99.70%
cost and expenses	18.98M -	41.76M 120.04%	66.77M 59.88%	102.31M 53.22%	110.05M 7.57%	121.93M 10.79%	129.70M 6.37%	155.97M 20.25%
operating expenses	18.98M -	41.76M 120.04%	66.77M 59.88%	102.31M 53.22%	110.05M 7.57%	121.93M 10.79%	129.70M 6.37%	148.37M 14.40%
interest expense					12K -	37K 208.33%	1.24M 3,237.84%	4.04M 226.80%
ebitda	-18.16M -	-39.79M 119.16%	-61.62M 54.86%	-93.19M 51.23%	-99.37M 6.63%	-68.86M 30.70%	-118.45M 72.01%	-147.04M 24.14%
operating income	-18.98M -	-41.76M 120.04%	-65.58M 57.04%	-97.94M 49.34%	-106.02M 8.25%	-75.21M 29.06%	-120.43M 60.12%	-154.63M 28.40%
depreciation and amortization	823K -	1.97M 139.37%	3.96M 101.07%	4.75M 19.79%	6.64M 40.02%	6.35M 4.47%	1.98M 68.87%	7.59M 284.16%
total other income expenses net	230K -	386K 67.83%	809K 109.59%	3.51M 333.50%	703K 79.95%	127K 81.93%	741K 483.46%	16.14M 2,078.68%
income before tax	-18.75M -	-41.38M 120.68%	-64.78M 56.55%	-94.43M 45.79%	-105.31M 11.52%	-75.08M 28.71%	-119.69M 59.41%	-138.49M 15.71%
income tax expense			809K -	-3.51M 533.50%	-703K 79.95%	-127K 81.93%	-6.56M 5,065.35%
net income	-18.75M -	-41.38M 120.68%	-64.78M 56.55%	-90.93M 40.37%	-104.61M 15.05%	-74.95M 28.35%	-113.13M 50.93%	-138.49M 22.42%
weighted average shs out	20.09M -	20.09M 0%	8.92M 55.61%	33.55M 276.21%	37.79M 12.63%	78.89M 108.73%	90.92M 15.25%	115.53M 27.07%
weighted average shs out dil	20.09M -	20.09M 0%	8.92M 55.61%	33.55M 276.21%	37.79M 12.63%	78.89M 108.73%	90.92M 15.25%	115.53M 27.07%
eps	-0.93 -	-2.06 121.51%	-7.26 252.43%	-2.71 62.67%	-2.77 2.21%	-0.95 65.70%	-1.24 30.53%	-1.20 3.23%
epsdiluted	-0.93 -	-2.06 121.51%	-7.26 252.43%	-2.71 62.67%	-2.77 2.21%	-0.95 65.70%	-1.24 30.53%	-1.20 3.23%

NASDAQ:GRTS

Gritstone bio, Inc.

Last Close

0.66

26/07 20:00

Market Cap

63.26M

Beta: 0.54

Volume Today

570.34K

Avg: 633.40K

PE Ratio

−1.89

PFCF: −1.56

Preview